Objective To study the inhibiting effect of edaravone on experimental autoimmune encephalomyelitis (EAE) mouse model. Methods Sixty female C57BL / 6 mice were randomly divided into three groups: normal control group, EAE group, EAE + edaravone group (n=20), normal control group with PBS as a control. The application of myelin oligodendrocytes glial cells glycoprotein 35-55 and complete Freund’s adjuvant (CFA) and Mycobacterium tuberculosis antigens emulsions were made modeling in the later two groups. After 2 days immunization, EAE+edaravone group were injected at a dose of 5 mg/(kg·d) of edaravone. Three groups were monitored 20 days, daily weighing, feeding and incidence were observed, and neurological function was scored. Mouse spinal cord tissue was obtained for pathological examination after 20 days. Results In EAE+edaravone treated mice, compared with EAE mice, the incidence and neurological function scores were significantly low (P<0.05). The incidence in EAE group was 80%, while the incidence in EAE+ edaravone group mice was 45%. Monitored for 10 days, in EAE group mice, neural function score was 3.6±0.4, while in EAE+ edaravone group mice neural function score was 1.3±0.5. HE staining found a large number of inflammatory cell infiltration in EAE mice spinal cord, and white matter demyelination was obvious. Nevertheless edaravone group mice had fewer inflammatory cell infiltration, and no white matter demyelination. Conclusions Protective effect of edaravone on EAE is related to scavenging free radicals and reducing inflammation.